Invus

Investor type Venture Capital
Founders Raymond Debbane

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 166
Average round size
info
The average size of a deal this fund participated in
$89M
Portfolio companies 121
Rounds per year 4.49
Lead investments 22
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.27
Exits 40
Key employees 18
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 1985 was created Invus, which is appeared as VC. The main department of described VC is located in the New York. The fund was located in North America if to be more exact in United States.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Invus, startups are often financed by Polaris Partners, Versant Ventures, The Column Group. The meaningful sponsors for the fund in investment in the same round are Fidelity Management and Research Company, Polaris Partners, Redmile Group. In the next rounds fund is usually obtained by InterWest Partners, Wipro Technologies, Wing Venture Capital.

Among the most popular fund investment industries, there are Biotechnology, Software. Among the various public portfolio startups of the fund, we may underline Moderna Therapeutics, Kythera Biopharmaceuticals, Gossamer Bio For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.

The top amount of exits for fund were in 2019. The important activity for fund was in 2019. The real fund results show that this VC is 14 percentage points more often commits exit comparing to other companies. This Invus works on 14 percentage points less the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of 50 - 100 millions dollars. The typical startup value when the investment from Invus is 500 millions - 1 billion dollars. The fund is constantly included in 2-6 deals per year.

Besides them, we counted 18 critical employees of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Invus:
Typical Co-investors
Invus is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Invus:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
1apeiron Florida, Miami, United States
BBVA USA Alabama, Birmingham, United States
Chinergy Capital Anhui, China, Wuxi
DHG Holding Netherlands, Noord-Holland, North Holland
Dividend Gate Capital -
Exponent Private Equity England, London, United Kingdom
FISM Japan, Kanagawa Prefecture, Kawasaki
Holden Capital Australia, New South Wales, Sydney
Imagine Lab Argentina -
NBCi California, San Francisco, United States
Okinawa Development Finance Corporation Chiyoda, Japan
Seneca Partners Haydock, St. Helens, United Kingdom
Shanxue Zhishang Jijin China, Guangdong, Shenzhen
Smart Team Global Beijing, Beijing, China
The Waterloo Foundation Cardiff, United Kingdom, Wales
Universal Music Group California, Santa Monica, United States
VECTOR INC. Chiyoda, Japan
VenturEast Andhra Pradesh, Hyderabad, India
Voice Punch California, Santa Monica, United States
ZWC Partners China, Hong Kong, Hong Kong Island

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

MOMA Therapeutics

Biotechnology
Therapeutics
$150M10 May 2022 Cambridge, Massachusetts, United States

Onxeo

Biopharma
Biotechnology
Pharmaceutical
$9M06 Apr 2022 Paris, Ile-de-France, France

LifeMine Therapeutics

Biotechnology
Life Science
Therapeutics
$175M23 Mar 2022 Cambridge, Massachusetts, United States

PrognomiQ

Biopharma
Biotechnology
Health Care
Medical Device
$46M15 Mar 2022 San Mateo, California, United States

Septerna

Biotechnology
$100M27 Jan 2022 San Francisco, California, United States

Leyden Labs

Biotechnology
Life Science
Therapeutics
$140M25 Jan 2022 Amsterdam, North Holland, Netherlands

Korro Bio

Biotechnology
Pharmaceutical
$116M05 Jan 2022 Cambridge, Massachusetts, United States

Jumbotail

Beverages
E-Commerce
Food and Beverage
Food Products
Grocery
Internet Retail
Marketplace
Retail
$85M21 Dec 2021 Bengaluru, Karnataka, India

Jumbotail

Beverages
E-Commerce
Food and Beverage
Food Products
Grocery
Internet Retail
Marketplace
Retail
$83M20 Dec 2021 Bengaluru, Karnataka, India
News
Asher Bio Closes $108 Million Series B Financing

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.

Laronde Raises $440M in Series B Financing

– Laronde is a Cambridge, Mass.-based company advancing Endless RNA™ (eRNA) – a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body.
– The company raised $440m in Series B financing.
– The round was led by Flagship Pioneering, with participation from T. Rowe Price Associates, Inc., Invus, Canada Pension Plan Investment Board (CPP Investments), Fidelity Management & Research Company, funds and accounts managed by BlackRock, and Federated Hermes Kaufmann Funds, among others.
– The new investment will be used to advance the development of the company’s eRNA platform and a broad pipeline of programs across a number of therapeutic categories.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Invus?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: